IST5-002 inhibited STAT5 phosphorylation and reduced the growth and viability of several chronic myeloid leukaemia (CML) cell lines, including those resistant to current therapies. This evidence concerns the gene STAT5A and chronic myelogenous leukemia, BCR-ABL1 positive.